Post by Genezen
10,501 followers
Advanced Modalities: What Comes Next? At MassBio's recent R&D Reimagined: The Future for Advanced Modalities, Chief Technical & Commercial Officer Susan D'Costa joined industry leaders to explore what's next for cell and gene therapies, gene editing, and other advanced modalities. And one message came through clearly: ā”ļø Scientific innovation is moving faster than traditional development models. The discussion highlighted the need for: š¹ New clinical trial paradigms for ultra-rare diseases š¹ Stronger collaboration across the development ecosystem š¹ Scalable manufacturing strategies that can keep pace with innovation š¹ A sharper focus on getting therapies across the "valley of death" and into the hands of patients who need them most As a proud MassBio partner, Genezen is excited to talk with innovators at every stage about how manufacturing strategy, technical expertise, and early collaboration can help accelerate advanced therapies from concept to clinic. Watch the full panel video here: https://lnkd.in/g47E_KS2 #MassBio #CellTherapy #GeneTherapy #AdvancedModalities #CGT #Biotech #ManufacturingInnovation #RareDisease #Innovation
